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Abstract
The effect of administration of the D 2 antagonist sulpiride in three striatal areas (dorsal striatum, DS; nucleus accumbens, 
ACC; olfactory tubercle; OT) was studied in the so-called paw test. In the paw test two parameters are measured (the hindlimb 
retraction time (HRT) and the forelimb retraction time (FRT)) that model the therapeutic efficacy and the extrapyramidal side 
effects of neuroleptics, respectively. Sulpiride significantly enhanced the HRT in each of the three structures. Identical doses of 
sulpiride administered in the three structures produced similar effects. The FRT was enhanced after administration of sulpiride 
in the DS and in the ACC, The minimal effective dose was lower for the DS. Administration of sulpiride in the OT did not affect 
the FRT. The effects on the FRT were very slow in onset (strong effects 4 h or more following administration of sulpiride), 
especially in comparison to the rapid effect on FRT following systemic administration of classical neuroleptics. To analyze this 
slowness of effect, two additional experiments were performed: first, the inter-trial time was changed so that it was identical to
that used in systemic studies; second, sulpiride was administered simultaneously in the DS and the ACC. Neither experiment 
produced an earlier effect on the FRT. The present data provide additional evidence for the theory that regional selectivity of 
drugs determines their propensity to induce extrapyramidal side effects. However, the data also suggest that the generally held
view that the dorsal striatum is solely responsible for the extrapyramidal side effects oi neuroleptic drugs is too si
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1. Introduction
A large number of studies have shown that classical 
and atypical neuroleptics can be discerned with respect 
to their regional selectivity. Thus, chronic administra­
tion of atypical 
firing in dopamine A 10, but not A9 cells, while classi­
cal neuroleptics affect both A10 and A9 cells [4,23' 
Atypical neuroleptics selectively block locomotor activ­
ity induced by dopamine in the nucleus accumbens 
(ACC) as compared to locomotor activity induced by 
dopamine in the dorsal striatum [7] (DS). These in vivo 
behavioural and electrophysiological findings are sup­
ported by pharmacological studies showing that atypi-
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cal neuroleptics affect spiperone binding in the ACC
• OT stronger than in the DS, while the reverse
neuroleptics [1,16,17], but see 
, most studies suggest that drugs 
the striatal AH) system (ACC and 
OT) have a low propensity to induce EPS (viz. atypical
On the
tics
• hand, regional selectivity of neurolep-
within the A 10 system: classical
activity
ACC stronger than that elicited from the OT, 
reverse is true for atypical neuroleptics [5,6]. latter
neur s not
ity system vs. dopamine Alt)
systems, but show selectivity within 
well. To further characterize the 
ACC and the OT, the present study 
the role of these structures in the 
model with
of the DS, the
test, an animal 
the antipsy-
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chotic potential (the hindlimb retraction time) and the 
extrapyramidal side effects (the forelimb retraction 
time) of drugs [9-11]. The effects of intracerebral 
administration of sulpiride, a D 2 selective antagonist 
and neuroleptic, are determined.
The results show that sulpiride affects the hindlimb 
retraction time after administration in all three areas, 
whereas the forelimb retraction time is especially af­
fected after administration of sulpiride into the DS. 
However, the effects of sulpiride on the forelimb re­
traction time were slow in onset, in comparison with 
systemic administration of neuroleptics [11]. To analyze 
this slowness of effect, two additional experiments were 
performed: first, the inter-trial time was changed so 
that it was identical to that used in systemic studies 
[11]; second, sulpiride was administered simultaneously 
in the DS and the ACC, two areas involved in the 
effects of sulpiride upon the forelimb retraction time. 
However, the results show that these additional experi­
ments did not change the slow onset of the effect on 
the forelimb retraction time .
2. Materials and methods
2.1. Subjects and surgery
Naive, Wistar rats (n = 7-12 animals per
group; Central Animal Laboratory, Nijmegen) were
Rats weighing between 180-220 g were anaes- 
with sodium pentobarbital (Narcovet, 60 
m g/kg, i.p.) and placed in a stereotaxic apparatus. 
Guide cannulas (outer diameter: 0.65 mm; inner diam­
eter: 0.30 mm) were bilaterally implanted into the DS 
(ant. 9.4, vert. 1.0, lat. 2.5), the ACC (ant. 9.8, vert. 2.7, 
Iat. 1.2) and the OT (ant. 8.8, vert. 1.1, lat. 2.2) [14], 
Cannulas (5 mm length) directed at the ACC were
angled 10 degrees laterally, while cannulas directed at 
the DS (4 mm length) and OT (6 mm length) were not 
angled. Cannulas were fixed onto the skull with dental 
cement (Durelon, ESFE; carboxylate cement) aided by 
the attachment of two screws. In an additional experi­
ment, every animal received four cannulas: two aimed 
bilaterally at the ACC (cannulas implanted at ant. 9.8 
mm, vert. 0.0 mm, lat. 1.0 mm, no lateral angle), and 
two the DS (cannulas implanted at ant. 9.4, vert. 0.0 
mm, lat. 2.5, vertical angle 10°). After surgery the rats 
were housed individually in the original stockroom and 
allowed recovery from operation for at least one week. 
Rats were kept on a 12-h day/night cycle with lights on 
at 07.00 h. Food and water were available ad libitum.
2 . 2 . K
At the day of the experiment, rats received bilateral 
injections of DL-sulpiride (Sigma; dissolved in distilled
water and a drop of acetic acid after which the pH was 
adjusted to 6 -7 ) in the DS, the ACC or the OT at
t means
mm
brain tissue below the tip of the permanent embedded
cannula (0.5 mm for DS; 1.0 mm for ACC; 1.5 mm for 
OT). The volume was 0.5 ¡x\ injected over a 10 s 
period, and the needle was left in situ for another 10 s 
to minimise diffusion along the needle tract. Then, the 
inner cannula was re-inserted. Earlier studies have 
shown that this procedure leads to highly localized 
injections [20]. In the experiment in which rats with 
four cannulas were used drugs were first injected into 
the ACC, immediately followed by bilateral injections 
into the DS. The paw test was performed at t =  30 and 
repeated at t =  60, 90, 120, 180, 240, 300 and 360 min
for each rat (in one additional experiment, the inter­
trial time was limited to 10 min, so that the paw test
was performed at t =  30, 40, 50, 60, 70, 80, 90 and 100
min).
Testing occurred between 09.00 and 17.00 h. Ani­
mals were only used for a single experiment. In the 
paw test a rat was placed on a Perspex platform, 
measuring 30 by 30 cm with a height of 20 cm and 
having four holes, two holes of 5 cm diameter for the 
hindlimbs and two holes of 4 cm for the forelimbs [11]. 
The rat was placed on the platform by positioning first 
the hind- and then the forelimbs in the holes. Two 
variables were measured in this test, namely the time it 
takes the animal to retract its first hindlimb (hindlimb 
retraction time; HRT) and the time it takes the animal 
to retract its first forelimb (forelimb retraction time; 
FRT) with a minimum time of 1 s and a maximum time 
of 30 s. Since only robust effects are considered to be 
important, the window (1 to 30 s) was chosen so that 
significant increases and significant decreases could be 
e
2.3. Data representation and statistics
The data are presented as the median value of the 
scores per group (/i = 7 - l l  rats) together with the 
standard error of the median, since the data showed no 
normal distribution. The individual scores were trans­
formed to ranks and statistically analyzed, using the 
SAS statistical package. Drug effects were analyzed 
with a repeated nonparametric analysis of variance 
(ANOVA) with factors drug and time. Since we are 
only interested in drug effects, a significant effect on 
the factor time will not be mentioned. For dose-depen­
dent effects, identical statistical analysis was per­
formed, but now with factors dose and time. Finally, in
ic ANOVAthe last experiment, a repeated 
was performed on the rank-transformed data with fac­
tors interval (duration) and 
section 3). After the
trials
îriments rats
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and brains were dissected. Brain sections were micro­
scopically analyzed. Only data from subjects with injec­
tions made into the desired sites (Fig. 1) were further 
analyzed.
3. Results
produced the (Fig. 4A). The
effects of 200 ng sulpiride in the last trial in our normal 
paradigm (testing at 30, 60, 90,...,360 min) were not 
different from the effects in the last trial in the 
paradigm with the short inter-trial interval of 10 min 
(testing at 30, 40,.., 100 min) both for the DS and the 
ACC (data not shown).
3.1. Effects of intra-striatal 
on the HRT
of sulpiride 3.2. Effects of intra-striatal
on
'nistration of s
In the DS, 25 ng sulpiride significantly enhanced the 
HRT (F U7 = 37.5, P < 0.001; Fig. 2). A higher dose of 
sulpiride (100 ng) produced significant greater effects 
than the dose of 25 ng (FllH -  9.8, P <0.01; Fig. 2). 
This dose of 100 ng induced an optimum effect since a 
higher dose of sulpiride (400 ng) produced an effect 
that was significantly smaller compared with that of
100 ng in the DS (Fi n =  7.6; P  < 0.05; data not shown).
In the ACC, 25 ng sulpiride significantly enhanced the
HRT (FlM =  179.0, P < 0.001; Fig. 2). A  higher dose
of sulpiride (100 ng) produced significant greater ef­
fects than the dose of 25 ng (Fi n  =  10.7, P  < 0.01; Fig. 
2). Further enhancing the dose to 400 ng did not 
produce effects different from those of 100 ng (data 
not shown). In the OT, 25 ng sulpiride significantly
enhanced the HRT (F1.14 6.2, P <  0.05; Fig. 2). A
higher dose of sulpiride (100 ng) produced significant
greater effects than the dose of 25 ng {F 1,15 13.2,
P < 0.01; Fig. 2). Further enhancing the dose to 400 ng 
did not produce effects different from those of 100 ng 
(data not shown).
Sulpiride (200 ng) administration in both the DS 
and the ACC did not differ from sulpiride administra­
tion (200 ng) in the DS alone, viz. the ‘control’ group
(100 ng: = 65.3, P <  0.001; 400 ng: Fu17
1,16
The lowest dose of sulpiride tested (25 ng) did not 
affect the FRT in any of the three areas (data not 
shown). Higher doses of sulpiride (100-400 ng) pro­
duced significant effects after administration in the DS
= 50.7,
P < 0.001; Fig. 3). In the ACC, sulpiride in a dose of 
100 ng did not affect the FRT (Fig. 3). Further enhanc­
ing the dose of sulpiride in the ACC to 400 ng pro­
duced a significant effect compared with controls (F
= 9.2, P < 0.01; Fig. 3). In the OT, 100 or 400 ng of 
sulpiride induced no significant effects (data not 
shown). Sulpiride (200 ng) administration in both the 
DS and the ACC did not differ from sulpiride adminis­
tration in the DS alone, viz. the ‘control’ group that 
produced the strongest effects (Fig. 4B).
In contrast to what was expected (see Introduction), 
the effects of 200 ng sulpiride in the last trial in our 
normal paradigm (testing at 30, 60, 90,...,2 
significantly higher than the effects in the last trial of 
in the paradigm with the short inter-trial interval of 10 
min (testing at 30, 40,.., 100 min; Fig. 5): an interaction 
between interval and trials was found for both for the
7,<>i ”  3 -7 5 ,
were
DS (F7 w == 5.66, P < 0.001) and the ACC (F 
P < 0.01; Fig. 5).
Fig. 1. The areas in which the injection places were located for the dorsal striatum (A), the nucleus accumbens (B) and the olfactory tubercle (C) 
according to the atlas of Paxinos and Watson [19],
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The present results show that intracerebral injec­
tions of sulpiride can affect the parameters measured 
in the paw test. Before the implication of these find­
ings can be discussed it is relevant to recall the validity 
of the paw test parameters. As has been discussed at 
length in other papers [9-11] the paw test measures 
both forelimb retraction time (FRT) and hindlimb re­
traction time (HRT). The HRT represents an animal
model for the therapeutic effects of neuroleptic drugs:
[1] All tested neuroleptics increase HRT [9,11]; [2] No  
false positives or negatives have sofar been identified 
[9,11]; [3] There is a correlation between the potency of 
neuroleptics to affect HRT and to induce therapeutic 
effects in the clinic [9]; [4] Anticholinergic drugs do not 
affect the effects of neuroleptic drugs [10]; [5] Chronic 
treatment does not lead to tolerance towards the ef­
fects of neuroleptics on HRT [10] and [6] Benzodi­
azepines enhance the effects of neuroleptics [9]. Like­
wise, there is strong evidence that FRT represents a 
good animal model for the extrapyramidal side effects: 
[1] Only classical neuroleptics enhance FRT [9,11]; [2] 
Anticholinergic drugs antagonise the effects of neu­
roleptics on FRT [10] and [3] Chronic treatment re­
duces the effects of neuroleptics on FRT [10]. Taken 
these data together, it seems that the paw test repre­
sents a valid model for both the therapeutic and the 
extrapyramidal side effects of neuroleptic drugs.
4.2. Effects of intra-striatal administration of sulpiride 
on the HRT
administration
cal neuroleptics produces strong effects on the HRT in 
the paw test [11]. The present study examined (a.o.) to 
what extent administration of the D 2 antagonist 
sulpiride in distinct striatal areas could mimic such an 
effect. The present data show that administration of 
sulpiride into the DS, the ACC and the OT all pro­
duced strong effects on the HRT, that were largely 
comparable from a quantitative point of view. Thus, 
blockade of D 2 receptors in all three striatal areas may 
be responsible for the effects observed after systemic 
administration of D 2 antagonists. The effects of 
sulpiride administered in these areas are considered to
30 60  9 0  120 180 2 40 300 360 min
Fig. 2. The effects of local application of sulpiride in three striatal
areas on the hindlimb retraction time (HRT). Every animal was
repeatedly tested in the paw test at the time points shown. Median
values±S.E.M . of the HRT are given. (• )  Controls; ( o )  25 ng
sulpiride; ( □ )  100 ng sulpiride. A: dorsal striatum. B: nucleus accum- 
bens. C: olfactory tubercle.
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60 90  120 240 300 360 mm
Fig. 3. The effects of local application of sulpiride in two striatal 
areas on the forelimb retraction time (FRT). Every animal was 
repeatedly tested in the paw test at the time points shown. Median
values ±S.E.M. of the FRT are given. ( • )  Controls; ( a )  100 ng
sulpiride; ( □ )  400 ng sulpiride. A: dorsal .striatum. 13; nucleus accum-
be specific for the area studied, since sulpiride diffuses 
hardly following intracerebral administration [2,15]. On 
the other hand, one study found evidence that ( —
from the DS to the ACC [22]. 
However, it has to be noted that the dose of sulpiride 
used in this latter study (40 fig) was at least 100-fold 
higher than the highest dose used in the earlier-men- 
tioned studies as well as in the present study [22],
4.3. Effects of intra-striatal administration of sulpiride 
on the FRT
Systemic administration of classical, but not atypical, 
neuroleptics produces strong effects on the FRT in the 
paw test [11]. The present study examined to what 
extent intra-striatal administration of a D 2 antagonist 
could mimic such an effect. The present data show that 
administration of sulpiride into the DS and to a lesser
into the ACC" " I o n
Thus, striatal D , receptors, especially in the DS, but
30 SO 90 120 180 240 300 360 min
Fig. 4. The effects of local co-administration of sulpiride (200 ng) in 
the dorsal striatum (DS) and the nucleus accumbens (ACC') on the 
hindlimb retraction time (I-IRT) and forelimb retraction time (FRT). 
Every animal was repeatedly tested in the paw test at the time points 
shown. Median values ±S.E.M. of the FRT are given. (• )  Sulpiride in 
ACC, distilled water in DS; ( o )  sulpiride in DS, distilled water in 
ACC; ( □  ) sulpiride in DS and ACC.
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Fig» 5. The effect of different inter-trial intervals following local 
application of sulpiride (200 ng) in the dorsal striatum (A) and the 
nucleus accurnbens (B) on the forelimb retraction time (FRT), Every 
animal was repeatedly tested in the paw test at either 30, 60, 90, 120, 
180, 240, 300 and 360 min (•) or at 30, 40, 50, 60, 70, 80, 90 and 100 
min (o). Median values ±S.E.M, of the FRT are given.
also in the ACC, may be responsible for the effects in 
the paw test following systemic administration of D2 
antagonists. However, unlike the effects seen after
administration of D2 antagonists, sulpiride 
administered in the DS or ACC produced its effects on 
the FRT only after several hours of repeated testing. 
Similar delayed effects of sulpiride were reported on 
catalepsy [12], which is like the FRT an animal model 
for extrapyramidal side effects. The delayed effect on 
the FRT was not due to the large inter-trial interval
(30 or 60 min) that was used in the present study; a 
control experiment using the 10 min inter-trial interval 
that produces strong effects on FRT following systemic 
injections of classical neuroleptics [11], did not produce 
a faster increase in FRT (Fig. 5B). In fact, the 10 min 
interval produced significantly smaller effects com­
pared with our normal paradigm (30, 60..,, 360 min 
testing), showing that the strong increase in FRT found 
in the present study, is not a direct consequence of 
repeated testing. Alternatively, it is theoretically possi­
ble that this slowness of onset was due to diffusion of 
sulpiride to the DS and/or the ACC. In the present 
study, however, simultaneous administration of 
sulpiride in both the DS and the ACC produced effects 
with similar slow onset (Fig. 5). Therefore, it is unlikely
*
that the tardy effects of sulpiride were due to the slow 
diffusion of sulpiride to these two structures. The most 
logical explanation is that the very slow diffusion of 
sulpiride in the distinct areas itself and, thus, the 
amount of D 2 receptors blocked within these areas 
caused this slow onset effect. Indeed, extrapyramidal 
side effects, for which the FRT is a model (see below), 
are known to require the blockade of about 80% of D 2 
receptors [13].
Given the predictive validity of the paw test showing 
that the HRT is a model for the therapeutic efficacy of 
neuroleptics and that the FRT is a model for the 
extrapyramidal side effects of neuroleptics (see above), 
the present study may contribute to our understanding 
of the role of regional selectivity in the EPS profile of 
neuroleptics. In contrast to the general hypothesis that 
neuroleptics produce their therapeutic effects by block­
ing A10 dopaminergic cells and produce extrapyrami­
dal side effects by blocking A9 dopaminergic cells, our 
data suggest a more complicated picture. The fact that 
sulpiride administered in the DS, the ACC and the OT 
is equipotent in enhancing the HRT strongly suggests 
that all three regions equipotently contribute to the 
antipsychotic efficacy of neuroleptics. On the other 
hand, the finding that sulpiride administered in the DS 
is more potent than sulpiride administered in the ACC 
in enhancing the FRT strongly suggests that neurolep 
tics with selectivity for the A9 system over the AH) 
system have a relatively high propensity to induce EPS, 
and that the reverse holds true for neuroleptics with 
selectivity for the A 10 system (see Introduction). More­
over, since sulpiride administered in the OT is still less 
potent in inducing an increase in FRT than sulpiride 
administered in the ACC, these data also explain why 
neuroleptics with selectivity for the OT over the ACC 
have a lower propensity to induce EPS than neurolep­
tics with selectivity for the ACC over the OT [5,6]. 
Finally, it should be noted that extra-striatal areas may 
also play an important role in the therapeutic effects or 
side effects of neuroleptics, such as the hippocampus 
[3] and the prefrontal cortex [8].
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